{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:08:07Z","timestamp":1786730887701,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T00:00:00Z","timestamp":1658620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T00:00:00Z","timestamp":1658620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors (ICI) are a promising treatment, but may cause hyperprogressive disease and early death. The present study investigated early mortality factors in ICI monotherapy for lung cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>We retrospectively reviewed all patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) and treated with ICI monotherapy (nivolumab, pembrolizumab, and atezolizumab) between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. Early death was defined as patients who died within 60\u00a0days of ICI treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 166 patients were included. The majority of patients (87%) had an Eastern cooperative oncology group (ECOG) Performance status (PS) of 0\/1. There were 21 early deaths. Significant differences were observed in ECOG PS, the histological type, liver metastasis, tumor size, the white blood cell count, neutrophils (%), lymphocytes (%), the neutrophil-to-lymphocyte ratio in serum (sNLR), C-reactive protein (CRP), and albumin between the groups with or without early death. Univariate logistic regression analyses identified ECOG PS score\u2009\u2265\u20092, liver metastasis, tumor size\u2009\u2265\u20095\u00a0cm, neutrophils\u2009\u2265\u200969%, lymphocytes\u2009&lt;\u200922%, sNLR\u2009\u2265\u20094, CRP\u2009\u2265\u20091\u00a0mg\/dl, and albumin\u2009&lt;\u20093.58\u00a0g\/dl as significant risk factors for early death. A multivariate logistic regression analysis revealed that liver metastasis (Odds ratio [OR], 10.3; <jats:italic>p<\/jats:italic>\u2009=\u20090.008), ECOG PS score\u2009\u2265\u20092 (OR, 8.0; <jats:italic>p<\/jats:italic>\u2009=\u20090.007), and a smoking history (OR, 0.1; <jats:italic>p<\/jats:italic>\u2009=\u20090.03) were significant risk factors for early death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Liver metastases, ECOG PS score\u2009\u2265\u20092, and a non-smoking history are early mortality factors in ICI monotherapy for advanced or metastatic NSCLC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04215-7","type":"journal-article","created":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T16:02:38Z","timestamp":1658678558000},"page":"3139-3147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer"],"prefix":"10.1007","volume":"149","author":[{"given":"Eiji","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Kunishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nokihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,24]]},"reference":[{"key":"4215_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2020.12.026","volume":"152","author":"B Abbar","year":"2021","unstructured":"Abbar B, De Castelbajac V, Gougis P, Assoun S, Pluvy J, Tesmoingt C, Th\u00e9ou-Anton N, Cazes A, Namour C, Khalil A, Gounant V, Besse B, Zalcman G, Brosseau S (2021) Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer 152:109\u2013118","journal-title":"Lung Cancer"},{"key":"4215_CR2","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41590-020-0801-7","volume":"21","author":"HI Aksoylar","year":"2020","unstructured":"Aksoylar HI, Boussiotis VA (2020) PD-1(+) T(reg) cells: a foe in cancer immunotherapy? Nat Immunol 21:1311\u20131312","journal-title":"Nat Immunol"},{"key":"4215_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639","journal-title":"N Engl J Med"},{"key":"4215_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135","journal-title":"N Engl J Med"},{"key":"4215_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","volume":"112","author":"R Brody","year":"2017","unstructured":"Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J (2017) PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112:200\u2013215","journal-title":"Lung Cancer"},{"key":"4215_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2967\/jnumed.119.237768","volume":"61","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Mazziotti E, Toschi L, Lopci E (2020) Hyperprogressive disease in patients with non-small cell lung cancer treated with checkpoint inhibitors: the role of (18) F-FDG PET\/CT. J Nucl Med 61:821\u2013826","journal-title":"J Nucl Med"},{"key":"4215_CR7","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferte C (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res 23:1920\u20131928","journal-title":"Clin Cancer Res"},{"key":"4215_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2016.10.010","volume":"102","author":"AM Chapman","year":"2016","unstructured":"Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK (2016) Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer 102:122\u2013134","journal-title":"Lung Cancer"},{"key":"4215_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1186\/s12885-020-07206-4","volume":"20","author":"Y Chen","year":"2020","unstructured":"Chen Y, Hu J, Bu F, Zhang H, Fei K, Zhang P (2020) Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. BMC Cancer 20:707","journal-title":"BMC Cancer"},{"key":"4215_CR10","doi-asserted-by":"publisher","first-page":"6639366","DOI":"10.1155\/2021\/6639366","volume":"2021","author":"S Chen","year":"2021","unstructured":"Chen S, Gou M, Yan H, Fan M, Pan Y, Fan R, Qian N, Dai G (2021) Hyperprogressive disease caused by PD-1 inhibitors for the treatment of pan-cancer. Dis Markers 2021:6639366","journal-title":"Dis Markers"},{"key":"4215_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Fert\u00e9 C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C (2018) Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4:1543\u20131552","journal-title":"JAMA Oncol"},{"key":"4215_CR12","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M (2016) EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585\u20134593","journal-title":"Clin Cancer Res"},{"key":"4215_CR13","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Jr., Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB, (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550","journal-title":"Lancet"},{"key":"4215_CR14","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3892\/ol.2020.11785","volume":"20","author":"X Huang","year":"2020","unstructured":"Huang X, Chen Z, Zhang N, Zhu C, Lin X, Yu J, Chen Z, Lan P, Wan Y (2020) Increase in CD4(+)FOXP3(+) regulatory T cell number and upregulation of the HGF\/c-Met signaling pathway during the liver metastasis of colorectal cancer. Oncol Lett 20:2113\u20132118","journal-title":"Oncol Lett"},{"key":"4215_CR15","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.cllc.2017.09.002","volume":"19","author":"T Inoue","year":"2018","unstructured":"Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Kunimasa K, Kimura M, Suzuki H, Hirashima T, Atagi S, Imamura F (2018) Analysis of early death in japanese patients with advanced non-small-cell lung cancer treated with nivolumab. Clin Lung Cancer 19:e171\u2013e176","journal-title":"Clin Lung Cancer"},{"key":"4215_CR16","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H (2019) PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 116:9999\u201310008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4215_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00262-021-03018-y","volume":"71","author":"DH Kang","year":"2022","unstructured":"Kang DH, Chung C, Sun P, Lee DH, Lee SI, Park D, Koh JS, Kim Y, Yi HS, Lee JE (2022) Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Cancer Immunol Immunother 71:579\u2013588","journal-title":"Cancer Immunol Immunother"},{"key":"4215_CR18","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R (2017) Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 23:4242\u20134250","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4215_CR19","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/cancers11111699","volume":"11","author":"JY Kim","year":"2019","unstructured":"Kim JY, Lee KH, Kang J, Borcoman E, Saada-Bouzid E, Kronbichler A, Hong SH, de Rezende LFM, Ogino S, Keum N, Song M, Luchini C, van der Vliet HJ, Shin JI, Gamerith G (2019a) Hyperprogressive disease during anti-PD-1 (PDCD1)\/PD-L1 (CD274) Therapy: a systematic review and meta-analysis. Cancers (basel). 11(11):1699","journal-title":"Cancers (basel)."},{"key":"4215_CR20","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jtho.2019.05.033","volume":"14","author":"Y Kim","year":"2019","unstructured":"Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K (2019b) Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor. J Thorac Oncol 14:1608\u20131618","journal-title":"J Thorac Oncol"},{"key":"4215_CR21","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e48","volume":"20","author":"KH Kim","year":"2020","unstructured":"Kim KH, Hur JY, Koh J, Cho J, Ku BM, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC (2020) Immunological characteristics of hyperprogressive disease in patients with non-small cell lung cancer treated with anti-PD-1\/PD-L1 Abs. Immune Netw 20:e48","journal-title":"Immune Netw"},{"key":"4215_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12885-020-07727-y","volume":"21","author":"SR Kim","year":"2021","unstructured":"Kim SR, Chun SH, Kim JR, Kim SY, Seo JY, Jung CK, Gil BM, Kim JO, Ko YH, Woo IS, Shim BY, Hong SH, Kang JH (2021) The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. BMC Cancer 21:19","journal-title":"BMC Cancer"},{"key":"4215_CR23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/eji.202048966","volume":"51","author":"BM Ku","year":"2021","unstructured":"Ku BM, Kim Y, Lee KY, Kim SY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ (2021) Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. Eur J Immunol 51:956\u2013964","journal-title":"Eur J Immunol"},{"key":"4215_CR24","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H (2020) The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21:1346\u20131358","journal-title":"Nat Immunol"},{"issue":"2","key":"4215_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H (2022) Lactic acid promotes PD-1 expression in regulatory T&nbsp;cells in highly glycolytic tumor microenvironments. Cancer Cell 40(2):201\u2013218","journal-title":"Cancer Cell"},{"key":"4215_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC (2017) Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol 12:403\u2013407","journal-title":"J Thorac Oncol"},{"issue":"52","key":"4215_CR27","doi-asserted-by":"publisher","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","volume":"5","author":"JC Lee","year":"2020","unstructured":"Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA (2020) Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 5(52):eaba0759","journal-title":"Sci Immunol."},{"key":"4215_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC (2019) Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res 25:989\u2013999","journal-title":"Clin Cancer Res"},{"key":"4215_CR29","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819\u20131830","journal-title":"Lancet"},{"key":"4215_CR30","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","volume":"25","author":"M Offin","year":"2019","unstructured":"Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD (2019) Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res 25:1063\u20131069","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4215_CR31","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3390\/cancers13122935","volume":"13","author":"A Passaro","year":"2021","unstructured":"Passaro A, Novello S, Giannarelli D, Bria E, Galetta D, Gelibter A, Reale ML, Carnio S, Vita E, Stefani A, Pizzutilo P, Stati V, Attili I, de Marinis F (2021) Early progression in non-small cell lung cancer (NSCLC) with high PD-L1 treated with pembrolizumab in first-line setting: a prognostic scoring system based on clinical features. Cancers (basel). 13(12):2935","journal-title":"Cancers (basel)."},{"key":"4215_CR32","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, Investigators K (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833","journal-title":"N Engl J Med"},{"key":"4215_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265","journal-title":"Lancet"},{"key":"4215_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","volume":"11","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 11:955\u2013965","journal-title":"Onco Targets Ther"},{"key":"4215_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2020.05.021","volume":"146","author":"MF Sharpnack","year":"2020","unstructured":"Sharpnack MF, Cho JH, Johnson TS, Otterson GA, Shields PG, Huang K, Carbone DP, He K (2020) Clinical and molecular correlates of tumor mutation burden in non-small cell lung cancer. Lung Cancer 146:36\u201341","journal-title":"Lung Cancer"},{"key":"4215_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689076","volume":"12","author":"XL Zou","year":"2021","unstructured":"Zou XL, Li XB, Ke H, Zhang GY, Tang Q, Yuan J, Zhou CJ, Zhang JL, Zhang R, Chen WY (2021) Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer. Front Immunol 12:689076","journal-title":"Front Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04215-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:06:23Z","timestamp":1688213183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04215-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,24]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04215-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,24]]},"assertion":[{"value":"6 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Review Board of the National Hospital Organization Kochi Hospital (R3-3) and Tokushima University (3013\u20133) approved the study protocol. Informed consent was waived because of the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}